746670-92-8Relevant academic research and scientific papers
Discovery of a potent and orally bioavailable dual antagonist of CC chemokine receptors 2 and 5
Carter, Percy H.,Brown, Gregory D.,Cherney, Robert J.,Batt, Douglas G.,Chen, Jing,Clark, Cheryl M.,Cvijic, Mary Ellen,Duncia, John V.,Ko, Soo S.,Mandlekar, Sandhya,Mo, Ruowei,Nelson, David J.,Pang, Jian,Rose, Anne V.,Santella, Joseph B.,Tebben, Andrew J.,Traeger, Sarah C.,Xu, Songmei,Zhao, Qihong,Barrish, Joel C.
, p. 439 - 444 (2015/04/27)
We describe the hybridization of our previously reported acyclic and cyclic CC chemokine receptor 2 (CCR2) antagonists to lead to a new series of dual antagonists of CCR2 and CCR5. Installation of a γ-lactam as the spacer group and a quinazoline as a benz
Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert- butoxycarbonylamino)-2-(hydroxymethyl)-cyclohexylcarbamate using an iodolactamization as the key step
Campbell, Carlton L.,Hassler, Carla,Ko, Soo S.,Voss, Matthew E.,Guaciaro, Michael A.,Carter, Percy H.,Cherney, Robert J.
experimental part, p. 6368 - 6370 (2009/12/08)
(Chemical Equation Presented) An efficient enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl) cyclohexylcarbamate 2, an essential intermediate for a series of potent CCR2 antagonists, is described. The key step
Cyclic derivatives as modulators of chemokine receptor activity
-
Page/Page column 75, (2008/06/13)
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
-
Page/Page column 33, (2010/02/11)
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
